MedPath

A Phase 1 Study to Evaluate the Safety and Tolerability of BYON5667 Eye Drops in Healthy Subjects

Completed
Conditions
ocular side effects with ADCs
10015919
Registration Number
NL-OMON50780
Lead Sponsor
Byondis B.V.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
32
Inclusion Criteria

Healthy male and female subjects, aged from 18 to 75 years at the time of
signing informed consent.
Presence of two functional eyes.
Good physical and mental health.
Female subjects of childbearing potential: an acceptable effective method of
contraception must be used during the trial until the end-of-study (EOS ).

Exclusion Criteria

Presence or history of ocular disease or ocular trauma, or history of ocular
surgery including laser-therapy, or ocular signs or symptoms of systemic
disease , including current or prior pathology of eyelid or tear duct .
Amblyopia and color blindness are allowed.
Recent (within 2 months prior to signing informed consent) or current use of
eye drops, or other (systemic) medication that may affect the eye according to
the summary of product characteristics.
Use of contact lenses within 14 days before Day 1 and for the duration of the
study.
Known active microbial, fungal or viral infection if deemed clinically
significant by the investigator.
Subject is pregnant or lactating.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath